Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL312-3003 Garadacimab in Pediatric Hereditary Angioedema
2022-502386-13-00Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Behring. Primary endpoints: Number of subjects with treatment-emergent adverse events (TEAEs), Percent of subjects with treatment-emergent adverse events (TEAEs) and 6 more. Started Oct 2023; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2022-502386-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502386-13-00.